Elite Pharmaceuticals Inc., a health care company specializing in the pharmaceutical sector, is headquartered in Northvale, United States. The company is engaged in the research, development, licensing, and manufacturing of both new and generic oral controlled-release pharmaceutical products. Its product portfolio includes pain management solutions currently in clinical trials, as well as therapeutic agents targeting cardiovascular, antidiabetic, and anti-infective conditions, alongside cough and cold preparations.
As of the latest available data, Elite Pharmaceuticals Inc. is publicly traded on the OTC Bulletin Board, with its shares priced at $0.45 as of January 27, 2026. The company’s stock has experienced significant fluctuations over the past year, reaching a 52-week high of $0.82 on June 17, 2025, and a 52-week low of $0.27 on April 6, 2025. The market capitalization of Elite Pharmaceuticals Inc. stands at approximately $483,523,360 USD.
In its most recent earnings call for Q2 2026, reported on November 18, 2025, the company highlighted substantial revenue growth. This financial performance is reflected in its current price-to-earnings (P/E) ratio of 34.62, indicating that the market values the company at approximately 34.62 times its earnings. Additionally, the price-to-book (P/B) ratio is 7.90, suggesting that the market values the company at nearly eight times its book value.
These financial metrics provide insight into the company’s market valuation relative to its earnings and book equity. Despite the absence of new public disclosures since the latest earnings call, the reported revenue growth and market valuation metrics underscore Elite Pharmaceuticals Inc.’s ongoing financial performance and market position.
For further information on the company’s activities and offerings, interested parties can visit their official website at www.elitepharma.com . Elite Pharmaceuticals Inc. has been a public entity since its initial public offering on July 23, 1998, and continues to focus on advancing its pharmaceutical product offerings in the health care sector.
